Rapid detection of tetracycline resistance in bovine Pasteurella multocida isolates by MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA)

Laura Van Driessche1, Jade Bokma1, Linde Gille1, Pieter-Jan Ceyssens2, Katrin Sparbier3, Freddy Haesebrouck4, Piet Deprez1, Filip Boyen4 & Bart Pardon1

Pasteurella multocida is notorious for its role as an opportunistic pathogen in infectious bronchopneumonia, the economically most important disease facing cattle industry and leading indication for antimicrobial therapy. To rationalize antimicrobial use, avoiding imprudent use of highly and critically important antimicrobials for human medicine, availability of a rapid antimicrobial susceptibility test is crucial. The objective of the present study was to design a MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA) procedure for tetracycline resistance detection in P. multocida. This procedure was validated on 100 clinical isolates with MIC-gradient strip test, and a comparison with disk diffusion was made. Sensitivity and specificity of the MBT-ASTRA procedure were 95.7% (95% confidence interval (CI) = 89.8–101.5) and 100% (95% CI = 100–100), respectively, classifying 98% of the isolates correctly after only three hours of incubation. Sensitivity and specificity of disk diffusion were 93.5% (95% CI = 86.3–100.6) and 96.3% (95% CI = 91.3–101.3) respectively, classifying 95% of the isolates correctly. In conclusion, this MBT-ASTRA procedure has all the potential to fulfill the need for a rapid and highly accurate tetracycline susceptibility testing in P. multocida to rationalize antimicrobial use in outbreaks of bronchopneumonia in cattle or other clinical presentations across species.

Pasteurella multocida, a Gram-negative coccobacillus, causes many important diseases in a wide range of hosts1. In different ruminant species and pigs it is one of the most frequently isolated pathogens in infectious broncho-pneumonia2–4, a disease which is the leading cause of morbidity and antimicrobial use in these species4. In more tropical regions of the world, especially Africa and Asia, P. multocida can also cause highly fatal hemorrhagic septicemia in cattle and buffaloes5. In other animal species, this bacterium has been associated with presentations like sepsis6, but also otitis7 and peritonitis8. In humans, P. multocida can cause several life-threatening conditions, like sepsis9 and endocarditis10.

Today, to control bronchopneumonia mass medication is still one of the preferred therapies in different food-producing animal species4,11,12. Given the issue of high level antimicrobial resistance in these industries and the one health initiatives founded to combat this13–15, preventative antimicrobial use is no longer consid-ered appropriate and antimicrobial treatment should be targeted16. In several European countries like Belgium, Germany or the Netherlands, guidelines suggest and legislation requires sampling and susceptibility testing of animal pathogens before specific antimicrobial agents can be used17–23. In addition, formularies have been

1Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium. 2National Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Juliette Wytsmanstraat 14, 1050, Elsene, Belgium. 3Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359, Bremen, Germany. 4Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium. Filip Boyen and Bart Pardon jointly supervised this work. Correspondence and requests for materials should be addressed to L.V.D. (email: Laura.Vandriessche@UGent.be)
initiated in several countries to guide veterinarians to select appropriate antimicrobials mainly based on their clinical efficacy and importance for human medicine. Especially in more intensive cattle rearing systems which rely on mass medication, antimicrobial multiresistance in *P. multocida* is common, hampering empiric antimicrobial therapy. Multiresistant isolates, that compromise 12 antimicrobial resistance genes, are threatening the future of these production systems.

To date, mainly disk diffusion susceptibility tests are used in veterinary practice to guide antimicrobial therapy. These take a minimum of 2 days after sampling before results are available, but in most cases, due to different practical reasons, a waiting period of 3–4 days is average. In most outbreaks of infectious bronchopneumonia postponing an appropriate therapy, until susceptibility testing results are available, is not acceptable for economic and animal welfare reasons. On the other hand initiation of an inappropriate antibiotic treatment will increase antimicrobial resistance selection pressure. Disk diffusion susceptibility tests have shown a sensitivity of only 85.7% for the detection of tetracycline resistance in *P. multocida* compared to the agar dilution technique as the gold standard in the past. Multiresistant isolates, that compromise 12 antimicrobial resistance genes, are threatening the future of these production systems.

Figure 1. Comparison of CAMHB (A) and BHIB (B) medium and different *P. multocida* starting concentrations to optimize bacterial growth to allow identification in an MBT-ASTRA procedure. Presented spectra are representative for the repetitions made using a single *P. multocida* isolate (P114, MIC: 0.19 µg/mL).
procedures are crucial. This to avoid unnecessary production loss, animal suffering or antimicrobial selection pressure.

The MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA) method, a MALDI-TOF MS-based approach for susceptibility testing, characterized by a semi-quantitative measurement of bacterial proteins, has shown promising results in obtaining rapid antimicrobial susceptibility results for human pathogens. For some fast growing bacteria involved in sepsis in humans only 1–4 hours are needed for susceptibility testing. Also for slow growers like mycobacteria this method seems viable. Furthermore, this technique shows a high sensitivity and specificity compared to minimum inhibitory concentration (MIC)-gradient strip test. The potential of MBT-ASTRA for veterinary indications, especially those associated with mass medication, has not been explored. Furthermore applying this method on fastidious growers like Pasteurella multocida or any other Pasteurellaceae has not yet been described.

Therefore, the primary objective of the present study was to design and validate an MBT-ASTRA procedure for tetracycline resistance detection in Pasteurella multocida from bovine origin. The secondary objective was to determine diagnostic accuracy of this MBT-ASTRA procedure and classic disk diffusion compared to MIC-gradient strip testing.

**Results**

**Determination of standard testing conditions for MBT-ASTRA.** To determine the optimal growth medium and starting concentration of the bacterial suspension, one susceptible isolate (P114: MIC: 0.19 µg/mL) was incubated in two different media using three different starting concentrations for incubation times varying between 0 and 6 hours (Fig. 1). This experiment was repeated two times. No difference in growth, expressed by
the area under the curve (AUC), was seen between Cation-adjusted Mueller Hinton broth (CAMHB) and Brain Heart Infusion broth (BHI) (Fig. 1). Starting concentration clearly affected growth, reaching sufficient bacterial growth for MALDI-TOF identification after 6, 2–4 and 0 h with 1.5 × 10^6 CFU/mL, 1.5 × 10^7 CFU/mL and 1.5 × 10^8 CFU/mL, respectively (Fig. 1).

Second, the antibiotic concentration allowing a clear separation between resistant and susceptible isolates was determined. To obtain this value, three susceptible (P114; MIC 0.19 µg/mL, P103; MIC 0.25 µg/mL and P113; MIC 0.5 µg/mL) and three resistant (P47; MIC 16 µg/mL, P162; MIC 24 µg/mL and P98; MIC 48 µg/mL) isolates of *P. multocida* were tested with tetracycline concentrations of 0, 2, 4 and 8 µg/mL and were incubated for 0, 3, 4, 5 and 6 hours. This experiment was performed 3 times independently, each using 1 resistant and 1 susceptible strain. After incubation, the growth derived from an increased protein signal of these isolates was calculated by measuring the AUC of the obtained spectrum. In the susceptible isolates, the AUC of the sample with antibiotic should be significantly reduced in comparison with the sample without antibiotic. For resistant isolates, no significant difference in AUC should be noticed. The relative growth (RG) ratio is the ratio of the AUC derived from spectra with and without antibiotic and is used to distinguish susceptible from resistant isolates according to an empirical cut-off value. A clear visual difference between susceptible and resistant isolates was achieved at a tetracycline concentration of 4 µg/mL and a RG cut-off value of 0.5 (Fig. 2). In this preliminary test, the three resistant isolates showed a RG > 0.5, while the susceptible isolates showed a RG < 0.5. A correct classification of all strains was already possible after 3 hours of incubation with 4 µg/mL tetracycline (Fig. 2).

**Determination of the diagnostic accuracy of the MBT-ASTRA procedure and comparison with the disk diffusion method.** *MIC distribution of the study population.* A total of 100 clinical *P. multocida* isolates were used to validate the MBT-ASTRA with the MIC-gradient strip test as reference test used in the current study. Of the isolates tested, 54 and 46 were classified as susceptible or resistant by MIC-gradient strip test, respectively. This experiment was conducted once. Tetracycline MIC-values for the quality control reference strains were tested twice and were in the acceptable range according to CLSI standards⁶, i.e. *Staphylococcus aureus* ATCC 29213 MIC-value 0.38 µg/mL and 0.5 µg/mL (range 0.12–1 µg/mL), *Escherichia coli* ATCC 25922 MIC-value 0.5 µg/mL and 1.5 µg/mL (range 0.5–2 µg/mL) and *Enterococcus faecalis* ATCC 29212 MIC-value 16 µg/mL (range 8–32 µg/mL). The tested isolates showed a bimodal MIC distribution, ranging between 0.094 and 48 µg/mL (Fig. 3). According to veterinary CLSI standards⁶, *P. multocida* isolates are considered responsive to treatment (=susceptible) with tetracycline in cattle when they show an MIC value ≤ 2 µg/mL.

**Diagnostic accuracy of MBT-ASTRA and disk diffusion.** The MBT-ASTRA procedure was conducted for 100 clinical isolates with an incubation time of 3 hours, with and without a tetracycline concentration of 4 µg/mL in CAMHB. This test was performed once. Relative growth values were determined for all tested isolates. Receiver operating characteristics (ROC) curve analysis showed a relative growth value of 0.5 to be the optimal cut-off to differentiate resistant from susceptible isolates for this MBT-ASTRA method (Fig. 4).

For the disk diffusion tests, quality control reference strains were included and inhibition zones (in mm) were in the acceptable range according to CLSI standards⁶, i.e. *Staphylococcus aureus* ATCC 25923 inhibition zone 24 mm (range 24–30 mm) and *Escherichia coli* ATCC 25922 inhibition zone 22 mm (range 18–25 mm). The disk diffusion method with quality control reference strains included was performed once.

Table 1 shows classification of the test results of both MBT-ASTRA and disk diffusion compared to the MIC-gradient strip test. At a RG cut-off value of 0.5, a correct classification of all 54 susceptible strains and 95.7%
(44/46) of resistant strains was achieved. All susceptible isolates showed RG values smaller than 0.5. All resistant isolates had RG values above 0.5, except two isolates (P33, P106) with an MIC value of 6 µg/mL that showed a RG value of 0.34 and 0.25 respectively, causing 2 false susceptible results.

Diagnostic accuracy of the disk diffusion and MBT-ASTRA method was calculated using the MIC-gradient strip test as reference (Table 2). Compared to MIC-gradient strip testing, the MBT-ASTRA method achieved a sensitivity and specificity of 95.7% and 100%, respectively. Sensitivity and specificity of disk diffusion were 93.5% and 96.3%, respectively. The essential agreement of MBT-ASTRA with the MIC-gradient strip test is 98%, due to 2% very major errors (Table 2). In contrast, the disk diffusion method obtained an essential agreement of 95%, including 3% very major errors and 2% major errors (Table 2).

**Table 1.** 2 × 2 Contingency table showing tetracycline resistance testing results of MBT-ASTRA and disk diffusion compared to MIC-gradient strip test for 100 recent clinical *P. multocida* isolates derived from cattle.

| Test          | Reference test (MIC-gradient strip test) |        |        |
|---------------|----------------------------------------|--------|--------|
|               | Resistant                               | 95.7% (44/46) | 0% (0/54) |
| MBT-ASTRA     | Susceptible                             | 4.3% (2/46)  | 100% (54/54) |
|               | Total                                   | 100% (46/46) | 100% (54/54) |
| Disk diffusion | Resistant                               | 93.5% (43/46) | 3.7% (2/54)  |
|               | Susceptible                             | 6.5% (3/46)  | 96.2% (52/54) |
|               | Total                                   | 100% (46/46) | 100% (54/54) |

**Figure 4.** Scatter plot of minimum inhibitory concentrations (MIC) obtained with the MIC-gradient strip test with MBT-ASTRA relative growth (RG) values of 100 recent bovine clinical strains of *P. multocida*. MBT-ASTRA testing conditions were 3 hours of incubation with a concentration of tetracycline of 4 µg/mL. The horizontal and vertical line represent the clinical breakpoint of ≤ 2 µg/mL and the RG cut-off value of 0.5, respectively. Two isolates with an MIC value of 6 µg/mL are considered susceptible with MBT-ASTRA, causing 2 false susceptible results.

**Discussion**

This study aimed at developing a MALDI-TOF MS-based approach for rapid tetracycline susceptibility testing in *P. multocida* and to compare this technique with the current standard test in practice (disk diffusion) with the MIC-gradient strip test. The most widely accepted gold standard for susceptibility testing in bacteria is the broth dilution technique. In order to compare the obtained data with previous studies, which commonly used the MIC-gradient strip test, the authors also opted for MIC-gradient strip testing. This is often considered as a near gold standard test. Therefore, the authors believe that current results based on the MIC-gradient strip test will hardly differ from broth dilution results. Further research can include latter technique as gold standard for determining the accuracy of the MBT-ASTRA method.

Another limitation was that no intermediate results were obtained from neither techniques. In practice, to avoid therapeutic failure, intermediate results are often regarded as resistant, and another antimicrobial is selected. As the MBT-ASTRA method is currently unable to correctly classify intermediate susceptibility isolates for a given antibiotic, including isolates with intermediate results on the reference test would have been an added value. Unfortunately, no isolates classified as intermediate by MIC-gradient strip test were obtained.
strains with an MIC value of 6 µg/mL can be classified as (borderline) resistant, resulting in 2% very major errors.

Although _P. multocida_ is considered a fastidiously growing microorganism by CLSI and tetracycline is considered bacteriostatic, which might cause a longer incubation time to obtain a clear difference in AUC with or without antibiotic. Due to this short incubation period, the MBT-ASTRA method makes it possible to provide the results of the susceptibility test on the same day of identification, avoiding unnecessary production loss or animal suffering. Sensitivity (95.7%) and specificity (100%) of the presented MBT-ASTRA procedure were excessive, in the range of and even higher than compared to previous findings applying MBT-ASTRA for other species under different conditions.

In contrast, the disk diffusion method evaluated in this study had lower sensitivity (93.5%) and specificity (96.3%). A previous study on _P. multocida_ isolates showed lower sensitivity (85.7%) and higher specificity (99.1%) of disk diffusion for tetracycline resistance detection. A possible explanation for this difference could be that at that time disks with higher tetracycline contents (80 µg) were used and clinical breakpoints differed with those obtained in the current study. Classification of the 100 isolates with disk diffusion was performed using the interpretative criteria of the manufacturer's guidelines. Currently, no _P. multocida_-specific clinical breakpoints for tetracycline in cattle are available for disk diffusion, while they are described for MIC testing. Zone diameters (mm) were measured and analysed. A clear difference between susceptible (zone diameter ranging from 24–32 mm) and resistant (zone diameter ranging from 8–10 mm) isolates was noticed. Due to these considerable differences in zone diameter, modifying the clinical breakpoints would have little to no effect on the results.

Compared to the disk diffusion method as used under the current circumstances, MBT-ASTRA shows less discrepancies to the MIC-gradient strip test method. However, in 2% of the isolates tested a very major error was present, potentially resulting in treatment of the animal with tetracycline when the isolate is resistant. Both of these isolates had an MIC value of 6 µg/mL. According to CLSI standards, an MIC value of 4 µg/mL is classified as intermediate and an MIC value ≥ 8 µg/mL is classified as resistant. Considering these clinical breakpoints, both strains with an MIC value of 6 µg/mL can be classified as (borderline) resistant, resulting in 2% very major errors and a sensitivity of 95.7% with the MBT-ASTRA method. However, the clinical outcome of treatment with tetracycline of _P. multocida_ isolates with an MIC value of 6 µg/mL might be difficult to distinctly predict.

Given its rapid results and high diagnostic accuracy, this MBT-ASTRA technique has high potential to be used in the field as a decision aid to direct antimicrobial use in food animals. In order to fulfil this potential, the possibilities of obtaining a full susceptibility test (as many antimicrobials tested at once as in disk diffusion) need to be explored, and the practical issue of availability of a MALDI-TOF MS in the regional laboratories needs to be overcome. However, in recent years the use of MALDI-TOF MS has been advanced to a standard method in clinical microbiology laboratories, due to its rapid and low-cost characteristics. Considering the simple potential of the rapid results as well as the high diagnostic accuracy of this MBT-ASTRA method, the further development of this technology and its application in clinical practice is encouraged.
setup and short incubation time, the MBT-ASTRA method implements an early intervention of adequate antibiotic therapy, resulting in a cost-and–labour efficient tool like the disk diffusion method. Whether the current MBT-ASTRA settings are also applicable to other Pasteurellaceae of clinical importance in veterinary medicine, like Mannheimia haemolytica or Histophilus somni, needs to be determined.

In conclusion, the MBT-ASTRA method developed in the present study, has all the potential to fulfill the need for a rapid and highly accurate tetracycline susceptibility testing in P. multocida. This is essential to rationalize antimicrobial use in outbreaks of bronchopneumonia in cattle or other clinical presentations across species.

Methods

Determination of the standard conditions for MBT-ASTRA. Selection of the optimal growth medium and starting concentration of P. multocida. BHIB (Difco, BD Diagnostic Systems, Sparks, Md.) and CAMHB (Difco, BD Diagnostic Systems, Sparks, Md.) were used as growth media in this study. One susceptible strain of P. multocida (P114, MIC 0.19 µg/mL) was inoculated in 10 mL of BHIB or 10 mL of CAMHB at different starting concentrations. Starting concentrations tested in both media were 1.5 × 10^6 CFU/mL, 1.5 × 10^7 CFU/mL and 1.5 × 10^8 CFU/mL. No antibiotics were added to the medium. All tubes were placed in a shaking incubator for 0, 1, 2, 3, 4 and 6 hours at a temperature of 37 °C and an atmosphere enriched with 5% CO₂. After each incubation period, 1 mL samples of each tube were transferred to Eppendorf tubes.

Selection of the optimal tetracycline concentration and incubation time. To determine the optimal concentration of tetracycline and the shortest incubation time necessary to differentiate between susceptible and resistant isolates, three susceptible isolates (P114, MIC 0.19 µg/mL, P103; MIC 0.25 µg/mL, P113; MIC 0.5 µg/mL) and three resistant isolates (P47; MIC 16 µg/mL, P162; MIC 24 µg/mL and P98; MIC 48 µg/mL) were used. Tetracycline concentrations of 0, 2, 4 and 8 µg/mL were tested (Sigma-Aldrich, Germany) at incubation periods of 0–3–4–5 and 6 hours.

MBT-ASTRA sample preparation. Eppendorf tubes, containing 1 mL samples prepared for the indicated incubation time, were centrifuged at 21130 × g for 5 minutes at room temperature. After centrifugation, the supernatant was carefully aspirated and 700 µL of 70% ethanol in high performance liquid chromatography (HPLC) graded water was added to the cell pellet and vortexed. A second centrifugation and aspiration of the supernatant was performed as mentioned above. After air drying for a minimum of 10 minutes, the cell pellets were stored at –20 °C for up to a maximum of 3 days. After storing, 20 µL 70% formic acid (in HPLC graded water) was added to the cell pellet and mixed carefully. Samples were incubated for five minutes at room temperature. In a last step, 20 µL of acetonitrile was added and vortexed. Before adding acetonitrile to the cell pellet, an internal standard 

MALDI-TOF MS analysis. One µL of the protein extraction was spotted in triplicate on the target plate (MS96 target polished steel BC). After air drying of the spots, 1 µL of matrix (10 mg/mL of α-cyano-4-hydroxy-cinnamic acid (α-HCCA) in 50% acetonitrile - 47.5% water - 2.5% trifluoroacetic acid; Bruker Daltonik GmbH, Bremen, Germany) was placed on each spot. External calibration was included in each measurement using a bacterial test standard (BTS, Bruker Daltonik GmbH, Bremen, Germany). Analysis was performed with an Autoflex III smartbeam MALDI-TOF MS instrument (Bruker Daltonik GmbH, Bremen, Germany), recording the mass range between 2.000–20.000 Da using standard settings. Automated data analysis was performed with the MBT-ASTRA software prototype written in the software package R35. A mass range of 2.500–13.500 was used for analysis. AUC and relative growth rate were calculated automatically for each setup. The duration of MALDI-TOF analysis is around 10–15 minutes for one sample. This duration is not cumulative when analysing multiple samples.

The obtained optimal test conditions were subsequently used during assay validation, analysing 100 recent clinical P. multocida isolates to determine the cut-off value of the relative growth ratio that allows a differentiation between susceptible and resistant isolates.

Determination of diagnostic accuracy of the MBT-ASTRA procedure and comparison with the disk diffusion method. Bacterial isolates and cultivation. In this experiment, 100 isolates of P. multocida from calves with bronchopneumonia collected in Belgium between 2014 and 2017 were analysed. Sampling of these calves was performed using a deep nasopharyngeal swab or a broncho-alveolar lavage as previously described44. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the ethical committee of the Faculty of Veterinary Medicine, Ghent University (EC 2014/164, EC 2016/20). Identification of P. multocida isolates was first achieved by standard biochemical tests44 and subsequently confirmed with MALDI-TOF MS using the direct transfer protocol as previously described46. Bacteria were cultivated overnight at 37 °C and an atmosphere enriched with 5% CO₂ on Columbia agar (Oxoid, UK) supplemented with 5% sheep blood.

Three susceptibility testing methods were performed on all isolates, namely MIC-gradient strip test, which is comparable to the standard dilution test32–34, the MBT-ASTRA procedure as described above and disk diffusion as the current standard test in practice.

MIC-gradient strip test. The MIC values of tetracycline were determined using MIC-gradient strips. Briefly, MIC test strips (Liofilchem, Italy) were placed on Mueller Hinton agar plates enriched with 5% defibrinated sheep blood (BD Diagnostics Systems), shortly after the plates had been uniformly inoculated via polyester swabs with 0.5 McFarland suspensions of the pure isolates. Incubation was performed for 18–24 hours under
aerobic conditions at 35 °C. *Staphylococcus aureus* ATCC 29213 and *Escherichia coli* ATCC 25922 were used as quality control reference strains. MIC values were determined according to the manufacturer’s instructions. Determination of susceptibility was performed according to the current CLSI standards for bovine *P. multocida* (i.e., susceptible ≤2 µg/mL, intermediate 4 µg/mL, resistant ≥8 µg/mL). Used media, incubation conditions, quality control strains and used interpretive criteria were applied according to CLSI standards. Inoculation method was performed according to manufacturer’s guidelines.

**MBT-ASTRA procedure.** All isolates were incubated for 3 hours with and without a tetracycline concentration of 4 µg/mL in CAMHB with a starting concentration of 1.5 × 10⁶ CFU/mL. MBT-ASTRA sample preparation and MALDI-TOF MS analysis were performed immediately after incubation as mentioned above.

**Disk diffusion test.** Susceptibility testing of *P. multocida* and tetracycline was performed in accordance with CLSI standards. Briefly, Mueller Hinton agar (Oxoid, UK) plates, supplemented with 5% sheep blood, were uniformly inoculated via polyester cline disks (30 µg/mL, Rosco, Neosensitabs, Taarstrup, Denmark) were placed on Mueller Hinton agar (Oxoid, UK) supplemented with 5% sheep blood, shortly after the plates had been uniformly inoculated via polyester swabs with 0.5 McFarland suspensions of the pure isolates. Incubation was performed for 18–24 hours at 35 °C in ambient air. Analysis of inhibition zones (in mm) was performed and interpretative criteria were according to manufacturer’s guidelines. *Staphylococcus aureus* ATCC 25923 and *Escherichia coli* ATCC 25922 were used as quality control reference strains.

**Statistical analysis.** Receiver operating characteristics (ROC) curve analysis was used to determine the optimal cut-off of the relative growth ratio to distinguish resistant from susceptible isolates in the MBT-ASTRA procedure (SPSS statistics vs. 24 (IBM, New York, United States)). Performance of the MBT-ASTRA and disk diffusion method compared to the MIC-gradient strip test as the gold standard was determined. Results were presented by distinguishing very major (resistant strain by the MIC-gradient strip test method misinterpreted as susceptible by the disk diffusion/MBT-ASTRA method), major (susceptible strain by the MIC-gradient strip test method misinterpreted as resistant by the disk diffusion/MBT-ASTRA method) and minor errors (intermediate result was obtained by only one method)41,47,48. Diagnostic accuracy, sensitivity, specificity, RPV and SPV were derived from 2 × 2 contingency tables using WinEpiscope 2.0.49.

**Availability of Data and Materials**

The authors declare that all information obtained from this study is presented in this paper.

**References**

1. Quinn, P. J., Carter, M. E. & Markey, B. *Pasteurella* species, In: Quin, ed. *Clinical Veterinary Microbiology*. Mosby International Limited, 254–258 (1994).
2. Woolums, A. R. The bronchopneumonias (respiratory disease complex of cattle, sheep, and goats). In: Smith BL, ed. *Large Animal Internal Medicine*. 5th ed. St. Louis, MO: Mosby Elsevier, 584–603 (2015).
3. Boyce, J. D., Seemann, T., Adler, B. & Harper, M. Pathogenomics of *Pasteurella multocida*. Current Topics in Microbiology and Immunology 361, 23–38, https://doi.org/10.1007/88-2012-203 (2012).
4. Pardon, B. et al. Prospective study on quantitative and qualitative antimicrobial and anti-inflammatory drug use in white veal calves. *Journal of Antimicrobial Chemotherapy* 67, 1027–1038, https://doi.org/10.1093/jac/dkr570 (2012).
5. Carter, G. R. & De Alwis, M. C. L. Haemorrhagic septicaemia. In: Adlam, C. and Rutter, J. M. eds. *Pasteurella and Pasteurellosis*. Academic Press, London, 131–160 (1989).
6. Malhi, P. S., Ngeleka, M. & Woodbury, M. R. Septicemic pasteurellosis in farmed elk (*Cervus canadensis*) in Alberta. *Canadian Veterinary Journal* 57, 961–963, PMCID: PMC4982567 (2016).
7. Jensen, R. et al. Cause and pathogenesis of middle ear infection in young feedlot cattle. *Journal of the American Veterinary Medical Association* 192, 967–972 (1983).
8. Catry, B. et al. Fatal peritonitis caused by *Pasteurella multocida* capsular type F in calves. *Journal of Clinical Microbiology* 43, 1480–1483, https://doi.org/10.1128/JCM.43.4.1480-1483.2005 (2005).
9. Konda, M. K., Chang, S. & Zaccheo, M. Purpura fulminans and severe sepsis due to *Pasteurella multocida* infection in an immunocompetent patient. *BMJ Case Reports*, https://doi.org/10.1136/bcr-2016-214891 (2016).
10. Yuji, D., Tanaka, M., Katayama & Kenichirou Noguchi, I. *Pasteurella multocida* infective endocarditis. *The Journal of Heart Valve Disease* 24, 778–779 (2015).
11. Timmerman, T. et al. Quantification and evaluation of antimicrobial drug use in group treatments for fattening pigs in Belgium. *Preventive Veterinary Medicine* 74, 251–263, https://doi.org/10.1016/j.prevetmed.2005.10.003 (2006).
12. Persoons, D., Dewulf, J. & Smet, A. et al. Antimicrobial use in Belgian broiler production and influencing factors. In: Persoons D., *Antimicrobial use and resistance in Belgian broiler production. PhD Thesis*. Ghent University, 2011. ISBN 978-90-5864-246-2.
13. Schrijver, R. et al. Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. *Clinical microbiology and infection* 24, 577–590, https://doi.org/10.1111/cmi.2017.09.013 (2018).
14. Mukerji, S. et al. Development and transmission of antimicrobial resistance among Gram-negative bacteria in animals and their public health impact. *Essays Biochemistry* 61, 23–35, https://doi.org/10.1042/EBC20160053 (2017).
15. Chantziaras, I., Boyen, F., Callens, B. & Dewulf, J. Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. *Journal of Antimicrobial Chemotherapy* 69, 827–834, https://doi.org/10.1093/jac/dkt443 (2013).
16. WHO guidelines on use of medically important antimicrobials in food-producing animals. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. http://www.who.int/foodsafety/publications/cia_guidelines/en/ (2017).
17. RD 21 July 2016, Filip, De Block M., Borsus W. Koninklijk besluit betreffende de voorwaarden voor het gebruik van geneesmiddelen door de dierenartsen en door de verantwoordelijken van de dienaren. 2016/169051025100953023.
18. FDA 2000. FDA Task Force on Antimicrobial Resistance: key recommendations and report, Washington, DC. FDA, Washington, DC: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM143458.pdf (2000).
19. Chantziaras, I., Boyen, F., Callens, B. & Dewulf, J. Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. *Journal of Antimicrobial Chemotherapy* 69, 827–834, https://doi.org/10.1093/jac/dkt443 (2014).
20. Avorn, J. L., et al. Antibiotic resistance: synthesis of recommendations by expert policy groups. Alliance for the prudent use of antibiotics. World Health organization (WHO/CDHS/CSR/DRS/2001.10) (2001).

21. No authors listed. Calls to restrict veterinary use of antimicrobials. *Veterinary Record* **171**, 10.1136/vr.e7755 (2012).

22. Fairies, J. The veterinarian’s role in antimicrobial stewardship. *The Canadian Veterinary Journal* **54**, 207–210 (2013).

23. https://www.jpiamr.eu/wp-content/uploads/2017/11/Report-_JPIAMR-workshop-on-Environmental-dimensions-of-AMR.pdf (2017).

24. Antimicrobial Consumption and Resistance in Animals (AMCRA) 2020. An ambitious, realistisch plan voor het antibioticumbeleid bij dieren to en met 2020. Retrieved from https://www.amcra.be/sites/default/files/bestanden/AMCRA%202020%20final/NL/20%20definitief_0.pdf (2015).

25. de Greeff, S. C. & Mouton, J. W. Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands. Lelystad, The Netherlands; 2017. Available at: https://www.vivm.nl/dsex/resource/objectid--f9799644-be6b-405b-b35f-c3dbb606c153bpdf&disposition=inline (2017).

26. Catry, B. et al. Detection of tetracycline-resistant and susceptible *Pasteurellaceae* in the nasopharynx of loose-group housed calves. *Veterinary Research Communication** 30, 707–715 (2006).

27. Catry, B. et al. Variability in acquired resistance of *Pasteurella* and *Mannheimia* isolates from the nasopharynx of calves, with particular reference to different herd types. *Microbial Drug Resistance** 11, 387–94, https://doi.org/10.1089/mdr.2005.11.387 (2005).

28. Hendriksen, R. S., et al. Prevalence of antimicrobial resistance among bacterial pathogens isolated from cattle in different European countries: 2002–2004. *Acta Veterinaria Scandinavica** 50, https://doi.org/10.1186/1751-0147-50-28 (2008).

29. Michael, G. B. et al. ICEPmu1, an integrative conjugative element (ICE) of *Pasteurella multocida*: analysis of the regions that comprise 12 antimicrobial resistance genes. *Journal of Antimicrobial Chemotherapy** 67, 84–90, https://doi.org/10.1093/jac/dkr406 (2012).

30. Marshall, B. M. & Levy, S. B. Food animals and antimicrobials: impacts on human health. *Clinical Microbiology Reviews** 24, 718–733, https://doi.org/10.1128/CMR.00002-11 (2011).

31. Catry, B., Dewulf, J. & de Kruijff, A. Accuracy of susceptibility testing of *Pasteurella multocida* and *Mannheimia haemolytica*. *Microbial Drug Resistance** 13, 204–211, https://doi.org/10.1089/mdr.2007.721 (2007).

32. Huang, M. B., Baker, C. N., Banerjee, S. & Tenover, F. C. Accuracy of the E-test for determining antimicrobial susceptibilities of *staphylococci*, enterococci, campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents. *Journal of Clinical Microbiology** 30, 3243–3248 (1992).

33. Baker, C. N., Stocker, S. A., Culver, D. M. & Thornberry, C. Comparison of the E-test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. *Journal of Clinical Microbiology** 29, 533–538 (1991).

34. Rennie, R. P., Turnbull, L., Brosnoff, C. & Cloke, J. First comprehensive evaluation of the MIC evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species. *Journal of Clinical Microbiology** 50, 1153–1157, https://doi.org/10.1128/JCM.05397-11 (2012).

35. Lange, C., Schubert, S. & Jung, J. Quantitative matrix-assisted laser desorption ionization-time of flight mass spectrometry for rapid resistance detection. *Journal of Clinical Microbiology** 52, 4155–4162, https://doi.org/10.1128/JCM.01872-14 (2014).

36. Sparhier, K., Schubert, S. & Kostrzewa, M. MBT-ASTRA: A suitable tool for fast antibiotic susceptibility testing? *Methods** 104, 48–54, https://doi.org/10.1016/j.ymeth.2016.01.008 (2016).

37. Jung, J., Hamacher, C. & Gross, B. Evaluation of a semi-quantitative matrix-assisted laser desorption ionization-time of flight mass spectrometry method for rapid antimicrobial susceptibility testing of positive blood cultures. *Journal of Clinical Microbiology** 54, 2820–2824, https://doi.org/10.1128/JCM.01131-16 (2016).

38. Maxson, T., Taylor-Howell, C. L. & Minogue, T. D. Semi-quantitative MALDI-TOF for antimicrobial susceptibility testing in *Staphylococcus aureus*. PLoS ONE **12**, https://doi.org/10.1371/journal.pone.0183899 (2017).

39. Ceyssens, P.-J., Soetaert, K. & Timke, M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for combined species identification and drug sensitivity testing in mycobacteria. *Journal of Clinical Microbiology** 55, 624–634, https://doi.org/10.1128/JCM.02089.16 (2017).

40. CLSI. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: Approved Standard-Fifth Edition. CLSI document VET01-S5. Wayne, PA: Clinical and Laboratory Standards Institute (2015).

41. Jørgensen, J. H. & Ferraro, M. J. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. *Medical microbiology** 49, 1749–1755, https://doi.org/10.1086/647952 (2009).

42. Hubert, S. K., Nguyen, P. D. & Walker, R. D. Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals. *Journal of Veterinary Diagnostic Investigation** 10, 164–168, https://doi.org/10.1177/104063879801000208 (1998).

43. Seng, P. et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clinical Infectious Diseases** 49, 543–551, https://doi.org/10.1086/600885 (2009).

44. Van Driessche, L., Valgaeren, B. & De Schutter, P. Effect of sedation on the intrapulmonary position of a bronchoalveolar lavage catheter in calves. *Veterinary Record** 179, https://doi.org/10.1136/vr.103676 (2016).

45. Quinn, P. J. et al. Antimicrobial agents. In: Quinn, ed. *Clinical Veterinary Microbiology*. Mosby International Limited, 1994, 254–258.

46. Kuhnert, P., Bugaard, M. & Korczak, B. M. Identification of animal *Pasteurellaceae* by MALDI-TOF mass spectrometry. *Journal of Microbiological Methods** 89, 1–7, https://doi.org/10.1016/j.mimet.2012.02.001 (2012).

47. Breteler, K. B., Rentenaar, R. J., Verkaart, G. & Sturm, P. D. Performance and clinical significance of direct antimicrobial susceptibility testing on urine from hospitalized patients. *Scandinavian Journal of infectious diseases** 43, 771–776, https://doi.org/10.1080/00365548.2011.588609 (2011).

48. Rhodes, N. J. et al. Unacceptably high error rates in Vitek 2 testing of cephepine susceptibility in Extended-Spectrum-3-Lactamase-producing *Escherichia coli*. *Antimicrobial Agents and Chemotherapy** 58, 3757–3761, https://doi.org/10.1128/AAC.00041-14 (2014).

49. Thrusfield, M., Ortega, C., de Blas, I., Noordhuizen, J. P. & Frankena, K. WIN EPISCOPE 2.0: improved epidemiological software for veterinary medicine. *Veterinary Record** 148, 567–572, https://doi.org/10.1136/vr.f148.1567 (2001).

Acknowledgements
This study was funded by a PhD Fellowship of the Research Foundation - Flanders (FWO-15S2616N). The MALDI-TOF mass spectrometer was financed by the Research Foundation Flanders (FWO-Vlaanderen) as Hercules project G0H2516N (AUGE/15/05). We thank Bruker Daltonik GmbH for providing internal standard.

Author Contributions
L.V. designed and conducted all experiments, collected literature data, analysed data, prepared figures and prepared the paper. J.B. conducted the validation study. P.-J.C. and K.S. supervised the work and provided insights in MBT-ASTRA sample preparation and MALDI-TOF MS analysis. P.D. supervised the work. F.B. and B.P. designed the study, analysed data, prepared figures and supervised the work. All authors read and reviewed the final manuscript.
Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018